SoftBank Builds a $5 Billion Stake in Pharma Giant Roche
This content was published on August 4, 2021 - 07:18
August 4, 2021 - 07:18
(Bloomberg) SoftBank Group Corp. has quietly built a $5 billion stake in Roche Holding AG, placing a bet on the pharmaceutical companyâs strategy of using data to develop drugs, according to people familiar with the matter.
The Japanese conglomerate is now one of Rocheâs largest investors, according to data compiled by Bloomberg.
Rocheâs sales have recently been boosted by its Covid-19 testing business. The companyâs diagnostics unit reacted swiftly to the coronavirus pandemic, but the pharmaceuticals division, where aging cancer medicines face increasing competition, has had a more difficult time.
âAllow Notificationsâ on the message appearing on your browser to activate them. We will send you a quick reminder in the future, in case you change your mind.
Molecular Biology Enzymes and Kits & Reagents Market worth $29.7 Billion by 2026 - Exclusive Report by MarketsandMarkets
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164131709
The Growth in the molecular biology enzymes and kits & reagents market is driven by factors such as increased research activities and R&D investments in the life science industry, rising number of genome projects, technological advancements in the life science industry, and rising incidence of genetic disorders.
The kits & reagents segment accounted for the largest share of the product segment in the molecular biology enzymes and kits & reagents market in 2020.
Based on products, the molecular biology enzymes and kits & reagents market is segmented into enzymes and kits & reagents. The kits & reagents segment accounted for the largest share of 85.9% of the global molecular biology enzymes and kits & reagents market in 2020. The large share of this segment can primarily be